Table of Contents

1. Zuclopenthixol
   1. Pharmacist Assessment Report
   2. Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Zuclopenthixol is a thioxanthene antipsychotic, originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is based on the computational model only.

Quick Overview

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, zuclopenthixol is a thioxanthene antipsychotic that antagonises dopamine D1/D2 receptors, with additional alpha-1 adrenergic and 5-HT2 receptor affinity. Its efficacy in schizophrenia is established.

No clear mechanistic link to the predicted indication has been identified. Retinal dystrophies are mostly monogenic disorders of photoreceptor or retinal pigment epithelium structure and function, and none of zuclopenthixol’s receptor activities addresses that pathology. The high TxGNN score reflects a TxGNN model (deep learning) prediction and should not be read as biological or clinical support.

Other high-ranking predictions were also reviewed (hydranencephaly, congenital disorder of glycosylation with defective fucosylation, Charcot-Marie-Tooth disease type 1G, several myopia entities, perisylvian polymicrogyria and atypical glycine encephalopathy). All are at evidence level L5 with no plausible mechanistic link and no trials or literature. The myopia entities have a speculative connection through retinal dopamine signalling, but dopamine antagonism would be expected to be unhelpful or counterproductive.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Some general points from the prediction review are worth noting. Zuclopenthixol’s CNS-depressant and seizure-threshold-lowering properties could be a concern in populations with encephalopathy or seizures. Antipsychotic-associated extrapyramidal symptoms could also complicate use in patients with neuropathies. No drug interaction records were found in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN model (deep learning) score, with no clinical trials, no literature and no plausible mechanistic link between dopamine/adrenergic/5-HT2 antagonism and retinal dystrophy pathology. A systemic antipsychotic is not justified for a largely monogenic retinal disorder without supporting evidence.

To proceed, the following is needed:

• Mechanism of action data and a credible mechanistic rationale for retinal dystrophy
• Preclinical or literature evidence supporting benefit in the predicted condition
• Approved indication text and safety information (warnings, contraindications) from the TGA-approved Product Information
• Route and formulation compatibility assessment (the only Australian product is a depot intramuscular injection)
• A drug interaction and safety review before any further consideration

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zopiclone
   1. Pharmacist Assessment Report
   2. Zopiclone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

Zopiclone: Known uses and market status in Australia

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Zopiclone, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is insomnia, which is supported by a licence in another country.

Quick overview

Known uses among the model’s candidates

Approved (supported by a licence or label)

Related to an approved indication (same disease category)

Relations recorded in the knowledge graph (no approval found)

Australia Market Information

Safety Considerations

Contraindication-related conditions (from drug–disease knowledge graph data, not label text): liver failure, anxiety disorder, neurotic disorder, dysthymic disorder.

Drug Interactions: 100 potential interactions were identified, but none has a severity grading (all are recorded as “Unknown”). Examples include morphine, scopolamine, metformin, glimepiride, pantoprazole, omeprazole and prednisone. Clinical significance cannot be determined from this data, particularly for additive CNS depression with opioids.

Literature-derived cautions: dependence and abuse potential, rebound insomnia on discontinuation, next-day cognitive impairment, falls and car accidents (especially in older adults). Short-term use only (generally up to four weeks) is recommended.

Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zonisamide
   1. Pharmacist Assessment Report
   2. Zonisamide: From Epilepsy to Tourette Syndrome
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Other Predicted Indications (Context)
   12. Disclaimer

Zonisamide: From Epilepsy to Tourette Syndrome

One-Sentence Summary

Zonisamide is an antiseizure medicine marketed in Australia as an oral capsule (the approved indication text was not available in the data compiled for this report). The TxGNN model predicts it may be effective for Tourette syndrome, but no clinical trials and no publications currently support this prediction. The prediction is model-based only and should be treated as a hypothesis.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, zonisamide acts on voltage-gated sodium and T-type calcium channels and may modulate dopaminergic and serotonergic transmission. These pathways could plausibly relate to the neural circuits involved in tics, but this link is speculative.

Its efficacy in epilepsy is established, and mechanistically it may be applicable to other neurological and neuropsychiatric conditions. However, no direct data link zonisamide to Tourette syndrome.

There is also a possible safety signal. A pragmatic review (PMID 36005856) reports antiseizure medication-induced tic disorder, which raises concern rather than offering support.

Clinical Trial Evidence

Currently no related clinical trials registered for Tourette syndrome.

Literature Evidence

Currently no related literature available for Tourette syndrome. The only relevant item identified, 36005856 (2022, Review, Expert Rev Neurother), discusses antiseizure medication-induced obsessive-compulsive disorder and tic disorder, which is a safety signal rather than evidence of benefit.

Australia Market Information

Safety Considerations

• Drug Interactions (100 interactions were identified; examples below):
  • Major: anticholinergic agents (methscopolamine, hyoscyamine, atropine, scopolamine, glycopyrronium, clidinium, dicyclomine, trospium, mepenzolate, propantheline) and metformin.
  • Moderate: aprepitant, morphine, dexamethasone, cimetidine, clarithromycin, dronabinol, nabilone, metoclopramide, miconazole.
• Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not label text): kidney disease and nephrolithiasis, liver disease, gallbladder disease, metabolic acidosis, neutropenia and agranulocytosis, and psychiatric disorders (anxiety, psychotic, schizoaffective and other mental disorders).

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as label text was not available.

Conclusion and Next Steps

Decision: Hold

Rationale: The Tourette syndrome prediction rests on the model score alone, with no trials or literature, and a related review flags possible tic induction by antiseizure medicines.

To proceed, the following is needed:

• Retrieve the TGA Product Information, including the approved indication, warnings and contraindications
• Obtain detailed mechanism of action data (for example from DrugBank)
• A systematic literature search and trial registry search (including ANZCTR) specific to Tourette syndrome
• Preclinical or small exploratory clinical evidence, with attention to tic-exacerbation risk

Other Predicted Indications (Context)

Other predictions were also reviewed, but none is stronger than L4 evidence:

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zolmitriptan
   1. Pharmacist Assessment Report
   2. Zolmitriptan: Atrophoderma vermiculata
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zolmitriptan: Atrophoderma vermiculata

One-Sentence Summary

Zolmitriptan is a triptan (5-HT1B/1D receptor agonist) that is already marketed in Australia for acute migraine. Evidence is limited to 0 registered clinical trials and general migraine and triptan literature. None of the supporting literature is specific to brainstem aura.

Quick Overview

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for zolmitriptan is not recorded in the data compiled for this report. The published reviews describe it as a selective 5-HT1B/1D agonist that acts on the trigeminovascular system, both peripherally and centrally. It has proven efficacy for acute migraine, with or without aura.

Migraine with brainstem aura is a subtype of migraine, so the same trigeminovascular mechanism could plausibly apply. This is the likely basis for the high model score.

There is an important caveat. Triptans have historically been used cautiously in brainstem aura (basilar-type) migraine because of theoretical concerns about vasoconstriction. The available literature consists of general migraine and triptan reviews and guidelines. It contains no study that directly supports or refutes zolmitriptan use in this subtype. The prediction is therefore a hypothesis to test, not a ready-to-use new indication.

Clinical Trial Evidence

Currently no related clinical trials registered for migraine with brainstem aura.

Literature Evidence

None of the publications below studies brainstem aura directly. They are the closest available evidence on migraine and triptans in general.

Australia Market Information

Safety Considerations

Product Information warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for label safety information. The items below come from the knowledge graph and interaction databases, not from label text.

• Contraindication signals (knowledge graph): These include:
  • hypertension
  • coronary artery disease, myocardial infarction and myocardial ischaemia
  • Prinzmetal angina
  • stroke, transient ischaemic attack, cerebral infarction and other cerebrovascular disorders
  • vertebrobasilar insufficiency
  • peripheral vascular disease and Raynaud disease
  • ischaemic bowel disease
  • Wolff-Parkinson-White syndrome
  • familial or sporadic hemiplegic migraine
  • kidney, liver and gallbladder disease
  • hemoglobinopathy
• Relevance to brainstem aura: Vertebrobasilar insufficiency and hemiplegic migraine appear in the contraindication list. This is consistent with the traditional caution about triptans in aura subtypes with brainstem symptoms.
• Drug interactions: 82 interactions were identified. Major-level interactions include:
  • lorcaserin
  • dolasetron
  • palonosetron
  • ondansetron
  • granisetron
  • dexfenfluramine
  • fenfluramine
  • sibutramine

  Most of these are serotonergic agents. Moderate-level interactions include morphine (including liposomal), cimetidine and obeticholic acid.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic argument is plausible, and zolmitriptan is already marketed in Australia for migraine. However, there are no clinical trials for brainstem aura, and none of the literature is specific to this subtype (evidence level L4). The vascular contraindication signals, including vertebrobasilar insufficiency, add to the safety uncertainty.

To proceed, the following is needed:

• Review of the TGA Product Information, including the approved indication and the warnings and contraindications for aura subtypes
• A targeted literature review and expert neurology input on triptan safety and efficacy in brainstem aura (basilar-type) migraine
• Mechanism of action data to support the mechanistic-link analysis
• If the hypothesis is pursued, a small, carefully designed clinical study with cardiovascular and cerebrovascular screening
• A drug interaction management plan, particularly for serotonergic co-medications

Other predictions from the same model run:

• For cluster headache, guidelines recommend triptans, including nasal or oral zolmitriptan. However, the zolmitriptan-specific trials are small or have uncertain status.
• These two indications may be better first candidates for further evaluation.

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zoledronic Acid
   1. Pharmacist Assessment Report
   2. Zoledronic Acid: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

Zoledronic Acid: Known uses and market status in Australia

Summary

All candidates that the TxGNN deep-learning model produced for Zoledronic Acid (score ≥ 0.99) and that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. The one known use is recorded as a knowledge graph relation.

Quick overview

Known uses among the model’s candidates

Approved (supported by a licence or label)

Related to an approved indication (same disease category)

Relations recorded in the knowledge graph (no approval found)

Australia Market Information

Safety Considerations

• Conditions linked to contraindication or caution (knowledge graph, not label text): anuria, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease, impaired renal function, intracranial haemorrhage, osteonecrosis of the jaw, hypophosphataemia, hypoparathyroidism, pulmonary oedema, fibromyalgia, myositis, tooth disease.
• Drug interactions: 100 interactions were found. Moderate-level examples include amphotericin B (including lipid, cholesteryl sulfate and liposomal forms), aminoglycosides (kanamycin, neomycin, streptomycin), vancomycin, polymyxin B, aspirin, mesalazine, balsalazide, olsalazine, sulfasalazine and exenatide. Several interact through additive renal or electrolyte effects. Interactions with unknown severity include calcitriol, vitamin A, pantoprazole, glimepiride and doxycycline.
• Calcium and vitamin D: Published case reports describe prolonged or severe hypocalcaemia after zoledronic acid, particularly with vitamin D deficiency. Vitamin D and calcium status should be corrected before use.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Ziprasidone
   1. Pharmacist Assessment Report
   2. Ziprasidone: Trichotillomania
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Ziprasidone: Trichotillomania

One-Sentence Summary

Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors. The TxGNN model predicts it may be useful for trichotillomania, with a score of 0.9983. The data compiled for this report contain no clinical trials and no publications that directly study this use, so the prediction rests on the model alone.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism of action data for ziprasidone are not available in the data compiled for this report. Ziprasidone is generally described as an antagonist at dopamine D2 and serotonin 5-HT2A receptors.

Trichotillomania is a repetitive hair-pulling (grooming) behaviour. Dopamine and serotonin dysregulation is plausibly involved in such behaviours, which gives a theoretical reason to expect a receptor-blocking antipsychotic might have an effect. This link is hypothetical. No study in the compiled data tests ziprasidone in trichotillomania, so the model score should be treated as a research signal, not as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

The drug is currently marketed in Australia as a single-ingredient oral product.

Safety Considerations

• Drug Interactions: The interaction data list 100 interacting drugs in total. The Major-level interactions among the entries reviewed include:
  • hydrocortisone
  • amphotericin B (including the lipid complex form)
  • bupropion
  • morphine

  Moderate-level interactions include several glucose-lowering agents (metformin, pioglitazone, alogliptin, albiglutide, acarbose) and anticholinergic agents (atropine, hyoscyamine, glycopyrronium).

• Conditions flagged for caution: Disease-level contraindication records, which are not label text, flag several conditions:
  • cardiac conditions: long QT syndrome, torsades de pointes, heart conduction disease, myocardial infarction and sudden cardiac arrest
  • orthostatic hypotension
  • epilepsy
  • liver failure and kidney disease
  • neutropenia and agranulocytosis
  • diabetes and diabetic ketoacidosis
  • hyperlipidaemia and obesity

Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the model score (0.9983) and a hypothetical dopamine/serotonin link. No trial or publication in the compiled data directly studies ziprasidone in trichotillomania, so the evidence level is L5. The cardiac (QT) and metabolic safety profile also argues against moving forward without supporting data.

To proceed, the following is needed:

• A structured literature search for ziprasidone, or other D2/5-HT2A antagonists, in trichotillomania and related repetitive grooming behaviours
• Mechanism of action data to support the hypothesised link
• Review of the TGA Product Information for warnings and contraindications, with a cardiac (QTc) and metabolic risk assessment for the target population
• Confirmation of the approved indication text for ARTG 9070J

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc Sulfate
   1. Pharmacist Assessment Report
   2. Zinc Sulfate: Pharyngitis
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zinc Sulfate: Pharyngitis

One-Sentence Summary

Zinc sulfate is a zinc salt used as a mineral supplement, and the approved indication is not recorded in the local data. The TxGNN model predicts it may be useful for pharyngitis, but the evidence is weak: 1 clinical trial on a related condition (postoperative sore throat) and 1 randomised trial in pharyngitis itself that found no benefit. The evidence level is L5.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Zinc is known to have local antiviral and mucosal-protective effects, and zinc lozenges release zinc ions directly in the oropharynx. Zinc may also support mucosal repair and taste or sensory recovery.

These mechanisms make a role in throat conditions plausible, but the link is indirect. The available studies address postoperative sore throat after intubation and radiation-induced mucosal injury, not infectious pharyngitis. The one randomised trial that studied pharyngitis directly (in radiotherapy patients) did not show a benefit, so the high model score is not supported by clinical findings.

Clinical Trial Evidence

Literature Evidence

Australia Market Information

At least one valid single-ingredient licence is recorded, and no licences are cancelled.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Drug Interactions: A total of 100 interactions were found in the interaction screen. Most of those listed are minor (for example, with corticosteroids and several biologic immunosuppressants). Moderate interactions include:

• Alendronic acid
• Risedronic acid
• Ibandronate
• Tetracycline
• Baloxavir marboxil

These moderate interactions are likely to involve reduced absorption when taken together, so dosing should be separated. Check this against the PI.

Conclusion and Next Steps

Decision: Hold

Rationale: The only randomised trial in pharyngitis itself found no benefit, and the other trial studied postoperative sore throat, a related condition. All direct evidence is therefore negative or absent, and the evidence level is L5. The high TxGNN score is not supported by clinical data.

To proceed, the following is needed:

• A controlled trial in infectious pharyngitis showing a clinical benefit
• Mechanism of action data
• Product Information warnings and contraindications for the Australian product, to allow safety screening
• Product, dosage form and indication details for the Australian licence

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc Oxide
   1. Pharmacist Assessment Report
   2. Zinc Oxide: Acne (disease)
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Other Predicted Indications (For Reference)
   12. Disclaimer

Zinc Oxide: Acne (disease)

One-Sentence Summary

Zinc oxide is a topical skin protectant, originally used for conditions such as dermatitis, fungal skin infections (tinea), haemorrhoids and burns. The TxGNN model predicts it may be effective for acne (disease), but there are no registered clinical trials and only 3 indirect publications supporting this direction. This is a computational prediction at an early research stage.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Based on known information, zinc oxide is a topical agent with established use as a skin protectant and soothing agent. It also has plausible anti-inflammatory, sebum-modulating and antibacterial activity, including against Cutibacterium acnes.

Acne is an inflammatory skin condition driven partly by bacterial colonisation. Zinc oxide’s existing uses in inflammatory and infective skin conditions (dermatitis, tinea, candidiasis) make a link to acne mechanistically conceivable.

The supporting literature is indirect, though. It consists of a general nanoparticle review, a preclinical microneedle study and a small split-face assessment whose relevance to zinc oxide cannot be confirmed. The very high TxGNN score is a computational output and does not replace clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Australia Market Information

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

The knowledge graph also lists associations with several conditions, including hypertension, benign prostatic hyperplasia, sickle cell anaemia, primary hyperoxaluria, iron metabolism disorders (haemochromatosis, haemosiderosis), Wilson disease, coronary artery disease, heart conduction disease, hyperthyroidism and anxiety. These come from graph relationships, not label text, and should be verified against the PI before any interpretation. No drug interaction records were found.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence is limited to indirect and preclinical sources, with no registered clinical trials. The high TxGNN score alone does not justify progression. The Australian listing also lacks the indication and product details needed for assessment.

To proceed, the following is needed:

• Mechanism of action data (for example from DrugBank)
• The TGA-approved PI for warnings, contraindications and approved indications
• Product details for the Australian listing (name, dosage form, indication)
• Human clinical data on topical zinc oxide in acne, such as a controlled trial or systematic review
• Confirmation of the relevance of the split-face study (PMID 15536660) to zinc oxide

Other Predicted Indications (For Reference)

Nine further predictions were reviewed. Most have no supporting evidence and a weak mechanistic rationale, so none is recommended for progression at this time.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc
   1. Pharmacist Assessment Report
   2. Zinc: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

Zinc: Known uses and market status in Australia

Summary

The TxGNN model has no candidate indication with a score of 0.99 or higher for Zinc, so there is currently no new predicted indication. The drug’s own recorded uses are listed below.

Quick overview

Known uses recorded for this drug

Approved (supported by a licence or label)

Related to an approved indication (same disease category)

Relations recorded in the knowledge graph (no approval found)

Australia Market Information

Safety Considerations

No warnings, contraindications or drug interaction data were available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zidovudine
   1. Pharmacist Assessment Report
   2. Zidovudine: From HIV Infection and AIDS to Feline Acquired Immunodeficiency Syndrome
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Australia Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zidovudine: From HIV Infection and AIDS to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Zidovudine is an antiretroviral medicine originally used to treat HIV infection and AIDS in people. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome (FIV/FeLV-related disease in cats), a veterinary condition. This is supported by 0 registered clinical trials and 20 publications, all animal studies.

Quick Overview

Why is This Prediction Reasonable?

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI). Detailed mechanism-of-action data were not available in the data compiled for this report. Based on its drug class, it is converted inside cells to an active triphosphate form that blocks the reverse transcriptase enzyme, which retroviruses need to replicate.

Feline immunodeficiency virus (FIV) is a lentivirus closely related to HIV. It replicates through the same reverse transcriptase-dependent process, so the mechanism is directly conserved. This explains the very high model score, and zidovudine has long been used experimentally in cats.

The prediction is a veterinary indication, so it is of limited relevance to human drug repurposing. It largely reflects the drug’s existing antiretroviral activity in a closely related animal model. The findings in the same-family simian immunodeficiency virus (SIV) model point the same way.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Australia Market Information

Safety Considerations

Disease associations recorded for zidovudine in the knowledge graph used by the model (these are not label text) include:

• Haematological: neutropenia, agranulocytosis, anaemia (including macrocytic anaemia)
• Hepatic and metabolic: liver disease and failure, fatty liver disease, non-alcoholic steatohepatitis, lactic acidosis, hypertriglyceridaemia, pancreatitis, gallbladder disease
• Muscle: myopathy, myositis, dermatomyositis, skeletal muscle disease
• Other: kidney disease, obesity disorders

Drug interactions: 100 interactions were recorded. The main ones are:

• Moderate: amphotericin B (including lipid and cholesteryl sulfate formulations), corticosteroids (betamethasone, budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, triamcinolone), statins (rosuvastatin, simvastatin), naltrexone and orlistat
• Minor: cimetidine and clarithromycin

Trial literature also describes pharmacokinetic interactions with probenecid and acetaminophen.

For full warnings and contraindications, please refer to the TGA-approved Product Information (PI).

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction is a veterinary indication supported only by animal studies, with no human trials. It is of limited value for human drug repurposing in Australia. The model’s high score mainly reflects zidovudine’s known antiretroviral mechanism.

Two lower-ranked predictions have direct human evidence, but they fall within the existing HIV indication family rather than being true repurposing. They are:

• AIDS-related complex: a completed Phase 3 trial (NCT00001011, 538 participants), which is historical because current practice uses combination antiretroviral therapy.
• Perinatal and congenital HIV: Phase 3 trials (NCT00102960, NCT00001104) and guideline-level evidence.

These two could proceed with guardrails: haematological monitoring, myopathy and lactic acidosis surveillance, DDI review, and monitoring for congenital malformations and neonatal haematological toxicity in pregnancy use.

To proceed, the following is needed:

• A clear scope decision on whether veterinary indications are in scope for this assessment
• Detailed mechanism-of-action data
• TGA Product Information warnings and contraindications, and the approved indication text for the ARTG entry
• For the human-relevant predictions, comparison against current Australian antiretroviral guidelines

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.